Fox Chase CB17 SCID Mouse

The Fox Chase CB17 SCID mouse is a well-characterized immunodeficient model extensively used in immunology, oncology, and transplantation research. This strain carries the Severe Combined Immunodeficiency (SCID) mutation, which eliminates functional T and B lymphocytes, rendering the mice incapable of mounting an adaptive immune response. They have normal NK cells, macrophages, and granulocytes.The designation CB17 refers to its genetic background: a BALB/c (C)- congenic strain carrying the Igh-1b allele from the C57BL/Ka (B) strain. The “17” indicates the specific substrain. The strain is similar to the BALB/c except its genetic background provides a balanced physiological profile, making the CB17 SCID mouse suitable for a wide range of experimental applications. Due to their profound immunodeficiency, these mice readily accept xenografts of human tumors, tissues, and cells, enabling researchers to develop humanized models for cancer biology, infectious disease studies, and stem cell research. Additionally, they serve as a critical platform for evaluating novel therapeutics, gene therapy approaches, and immune system function in the absence of adaptive immunity.The CB17 SCID strain was originally developed at the Fox Chase Cancer Center by Bosma in C.B-17/Icr mice and later transferred to Charles River in 1991 from an Iffa Credo foundation colony.Fox Chase SCID is a registered trademark of The American Oncologic Hospital.